



Immuron's Presentation from the RedChip Global Microcap Conference Available for Replay

10th November 2015, Melbourne, Australia: Immuron Limited (ASX: IMC) (OTCQB: IMROY), a biopharmaceutical company focused on oral immunotherapy using dairy-derived polyclonal antibody products for humans, today announced that its presentation from the RedChip Global Online Microcap Conference is now available for replay.

The replay of the presentation can be viewed by clicking on the following link:

<http://immuron.com/clinical-insights-and-updates/red-chip/>

A copy of the slide presentation is available at:

<http://www.asx.com.au/asxpdf/20151022/pdf/4328sn36wbpvd8.pdf>

The presentation by Immuron's CEO, Thomas Liquard, was recorded on October 22, 2015 and includes a question and answer session with investors that provides further detail on the Company's versatile immunotherapy technology platform.

About Immuron

Immuron Ltd is a publicly-listed Australian biopharmaceutical company (ASX: IMC) (OTCQB: IMROY) focused on oral immunotherapy using dairy-derived polyclonal antibody products for humans. Immuron is a uniquely positioned biotechnology company in view of its versatile technology platform, comprising dairy derived polyclonal antibodies, capable of generating a wide range of products with a high safety profile. This high safety profile makes it possible to complete pre-clinical studies relatively quickly and raises the prospect that the clinical development of Immuron's products will be expedited. For more information visit: <http://www.immuron.com/>

Contact:

Thomas Liquard
Chief Executive Officer
AUS Ph: +61 (0)3 9824 5254
thomasliquard@immuron.com

Immuron Investor Relations:

Jon Cunningham
RedChip Companies, Inc.
(407) 644-4256, ext. 107
jon@redchip.com

Forward-Looking Statements:

Certain statements made in this release are forward-looking statements and are based on Immuron's current expectations, estimates and projections. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements. Although Immuron believes the forward-looking statements are based on reasonable assumptions, they are subject to certain risks and uncertainties, some of which are beyond Immuron's control, including those risks or uncertainties inherent in the process of both developing and commercializing technology. As a result, actual results could materially differ from those expressed or forecasted in the forward-looking statements. The forward-looking statements made in this release relate only to events as of the date on which the statements are made. Immuron will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this release except as required by law or by any appropriate regulatory authority.